Johnson & Johnson (JNJ) Stock: Rebounds as ICOTYDE Delivers Strong Two-Year Psoriasis Results

TLDR

Table of Contents

JNJ stock rises 0.54% pre-market after falling 2.30% in the prior session.
ICOTYDE delivers sustained plaque psoriasis skin clearance through Week 112.
Seventy percent of patients achieved clear or almost clear skin by Week 112.
Complete clearance reached 89% for genital psoriasis and 60% for scalp cases.
Johnson & Johnson reports no new safety signals in the two-year ICOTYDE data.

Johnson & Johnson (JNJ) stock rose 0.54% to $260.21 in pre-market trading after falling 2.30% in the previous session. The rebound followed new two-year Phase 3 data for ICOTYDE in patients with plaque psoriasis. The results showed sustained skin clearance across several high-impact body areas through Week 112.

Johnson & Johnson, JNJ

ICOTYDE Sustains Clearance Through Week 112

Johnson & Johnson presented the findings from the Phase 3 ICONIC-TOTAL study at the EADV Congress 2026. The trial evaluated adults and adolescents with at least moderate psoriasis affecting difficult body sites. Those areas included the scalp, genitals, hands, and feet, where symptoms can disrupt daily activities.

ICONIC-TOTAL compared once-daily ICOTYDE with placebo during the controlled portion of the study. Participants receiving placebo switched to ICOTYDE after Week 16 under the study design. Researchers then followed treatment responses and safety outcomes across the longer study period.

Clear or almost clear skin rates improved as treatment continued. The response rate increased from 57% at Week 16 to 67% at Week 24. By Week 112, 70% reached an Investigator’s Global Assessment score of zero or one.

High-Impact Psoriasis Sites Show Broad Gains

Site-specific results also showed sustained improvement across several difficult psoriasis locations. Sixty percent of patients with scalp psoriasis achieved complete scalp clearance by Week 112. Meanwhile, 89% reached complete genital clearance after receiving ICOTYDE through the extended treatment period.

Patients with psoriasis affecting the hands or feet also recorded meaningful clearance. At Week 112, 63% achieved a hand or foot assessment score showing complete clearance. These results broadened the long-term evidence across areas that can prove difficult to manage.

Nail psoriasis improved further as treatment continued beyond the first year. Mean improvement in the modified Nail Psoriasis Severity Index reached 33% at Week 16. That measure increased to 62% at Week 52 and 71% at Week 112.

Johnson & Johnson Expands ICOTYDE Development

Johnson & Johnson reported no new safety signals through Week 112. The company said the findings remained consistent with ICOTYDE’s established safety profile. The longer follow-up adds safety data alongside the sustained skin clearance reported in the study.

ICOTYDE blocks the IL-23 receptor and uses a targeted oral peptide approach. Johnson & Johnson is studying the therapy across a wider Phase 3 development program. That program includes ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 in plaque psoriasis.

The company also continues trials across other immune-mediated conditions. Ongoing studies include psoriatic arthritis, ulcerative colitis, Crohn’s disease, and additional plaque psoriasis populations. The broader program could expand the clinical evidence supporting ICOTYDE across several inflammatory diseases.

✨ Limited Time Offer